Does pharma need a mission reset?
Michelle Nunn – President and CEO of Care USA – discusses how the public and private sectors can work together to ensure advances in pharma and medicine are accessible to all.
Drug discovery is the riskiest journey in science. It’s also one of the most important.
There are more than 70,000 ways for the human body to fail. Each one represents a treatment to be found. But life sciences is unpredictable, most new treatments fail. Every day brings challenges that can end the life of a drug before it is born.
Without risk, the explorer cannot advance. Reach too far and the journey is over.
Every step, Wolters Kluwer is with you.
To push is to risk. Keep pushing.
The toughest journey in science?
Drug discovery is the riskiest journey in science. It’s also one of the most important. There are more than 70,000 ways for the human body to fail. Each one represents a treatment to be found. But life sciences is unpredictable. Most new treatments fail. Every day brings challenges that can end the life of a drug before it is born. Without risk, the explorer cannot advance. Reach too far and the journey is over.
Every step, Wolters Kluwer is with you.
To push is to risk. Keep pushing.
The vast, evolving world of pharmaceutical research in the palm of your hand
Increased spending in pharmaceutical R&D is resulting in more drugs than ever before.
CFO Outlook: Pharma CFOs look beyond profit to long term value
An expert panel from EY and CCH® Tagetik addresses the unique challenges faced by pharma CFOs in this webinar.
Starting a durable medical equipment business
An aging population and the desire for patients to receive in-home care are fueling a surge in the durable medical equipment (DME) market.
Pharmacy Next: Consumer trends and industry transformation
US consumers increasingly trust non-traditional primary care providers for convenient and affordable healthcare.
Pharma Unlimited Podcast Series
Safety and efficacy at speed
Professor Sir John Bell – an instrumental figure in the delivery of the AstraZeneca vaccine – joins host Bertrand Bodson to talk about risk management in a post-pandemic world.
Big Tech – Friend or Foe?
Harvard Business School professor Karim Lakhani discusses the arrival of Big Tech on the pharma scene, and whether the future of medicine is about close competition or closer cooperation.
Can Big Tech de-risk personalized medicine?
Peter Lee – Corporate Vice President of Research and Incubation at Microsoft – joins to discuss how pharma companies can resolve the conflict between data-fuelled development and data privacy.
Can ethics keep pace with pharma innovation?
Klaus Moosmayer – Chief Ethics, Risk & Compliance Officer at Novartis – discusses how ethical standards in the pharma industry can be maintained and met in the face of such change.
Ovid
Medical Research Platform
Ovid’s medical research platform supports clinicians and researchers with trusted evidence-based information, leading search and discovery technology. Ovid delivers insights into the growing body of data used to drive critical decisions that improve patient care and clinical outcomes. Medical research teams focused on drug safety rely on Ovid when conducting discovery and regulatory compliance requirements that ensure patient safety.
CCH Tagetik
Corporate Performance Management
Covid-19 uncertainty is forcing greater agility and faster responses across the life sciences supply chain. CCH Tagetik enables faster, more accurate financial planning and analysis against multiple scenarios to drive more effective decision making.
CCH Tagetik empowers finance professionals with data-driven corporate performance management solutions that leverage diverse, granular data from across the enterprise to accelerate business performance.
TeamMate
Audit and Assurance Solution
TeamMate’s dedicated audit solutions deliver the assurance life sciences companies need to operate in a continuously changing regulatory environment. Audit professionals rely on TeamMate to build a single, complete picture of the whole audit workflow, enhancing strategic decision making and helping to uncover insights that identify and mitigate risk.
ELM Solutions
Legal Spend and Matter Management
The tough nature of drug discovery means litigation is a matter of when rather than if. ELM ensures exposure can be controlled in the most complex environments, enabling pharma legal departments to prepare, budget and manage a range of critical legal issues, from contract compliance to the selection of the most appropriate outside counsel.
CT Corporation
Business License Solutions
The Pharmacy industry is regulated by both federal and state law. Every state in the U.S. requires pharmacies to be properly licensed before they can legally operate within its borders. The type of pharmacy license required depends specifically on the activity being conducted. CT Corporation is familiar with the licensing laws and requirements of each state. We can streamline the application process for your pharmacy, ensuring that you are fully compliant with all registration requirements.
Enablon
Risk Management Software
In the high-risk environment of life sciences, Enablon supports the evaluation and mitigation of operational risk, helping pharma companies to control lab safety and deliver higher quality, more sustainable products.
Enablon helps to predict and prevent critical incidents and improve decision making across the business, keeping employees safe, and the organization fully compliant.